Islet amyloid polypeptide is not a satisfactory marker for detecting pancreatic cancer

Suresh T Chari, George G. Klee, Laurence J Miller, Massimo Raimondo, Eugene P. DiMagno

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Background & Aims: Islet amyloid polypeptide (IAPP) levels are elevated in pancreatic cancer and may be a useful marker of pancreatic cancer-associated diabetes. The aim of this study was to compare the sensitivity and specificity for pancreatic cancer of IAPP with that of CA19-9, examine clinical characteristics of diabetes in pancreatic cancer, and define the relationship of lAPp to diabetes of pancreatic cancer. Methods: Fasting serum glucose, IAPP, and CA 19-9 were measured in 130 subjects with pancreatic cancer, 250 subjects with other pancreatic and peripancreatic diseases, and 116 controls. In pancreatic cancer patients, we noted tumor stage and the presence and duration of diabetes. Results: IAPP was markedly elevated in pancreatic cancer, especially in patients with diabetes. However, the sensitivity of IAPP for pancreatic cancer was less than that of CA 19-9 (40% vs. 75%; P < 0.001). Diabetes was present in 46% of pancreatic cancers and 55% of resectable tumors. In pancreatic cancer with diabetes, the sensitivity of IAPP was only 50%. In resectable cancer it was 27%. Conclusions: IAPP is elevated in pancreatic cancer but is not sensitive enough to replace or complement existing tests. Diabetes occurs early and frequently in pancreatic cancer. Development of a sensitive and specific marker for pancreatic-associated diabetes might lead to diagnosis of resectable pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)640-645
Number of pages6
JournalGastroenterology
Volume121
Issue number3
StatePublished - 2001

Fingerprint

Islet Amyloid Polypeptide
Pancreatic Neoplasms
Neoplasms
Pancreatic Diseases
Islets of Langerhans

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Islet amyloid polypeptide is not a satisfactory marker for detecting pancreatic cancer. / Chari, Suresh T; Klee, George G.; Miller, Laurence J; Raimondo, Massimo; DiMagno, Eugene P.

In: Gastroenterology, Vol. 121, No. 3, 2001, p. 640-645.

Research output: Contribution to journalArticle

Chari, Suresh T ; Klee, George G. ; Miller, Laurence J ; Raimondo, Massimo ; DiMagno, Eugene P. / Islet amyloid polypeptide is not a satisfactory marker for detecting pancreatic cancer. In: Gastroenterology. 2001 ; Vol. 121, No. 3. pp. 640-645.
@article{7fe6240cb7124ed4988274c1982e20ce,
title = "Islet amyloid polypeptide is not a satisfactory marker for detecting pancreatic cancer",
abstract = "Background & Aims: Islet amyloid polypeptide (IAPP) levels are elevated in pancreatic cancer and may be a useful marker of pancreatic cancer-associated diabetes. The aim of this study was to compare the sensitivity and specificity for pancreatic cancer of IAPP with that of CA19-9, examine clinical characteristics of diabetes in pancreatic cancer, and define the relationship of lAPp to diabetes of pancreatic cancer. Methods: Fasting serum glucose, IAPP, and CA 19-9 were measured in 130 subjects with pancreatic cancer, 250 subjects with other pancreatic and peripancreatic diseases, and 116 controls. In pancreatic cancer patients, we noted tumor stage and the presence and duration of diabetes. Results: IAPP was markedly elevated in pancreatic cancer, especially in patients with diabetes. However, the sensitivity of IAPP for pancreatic cancer was less than that of CA 19-9 (40{\%} vs. 75{\%}; P < 0.001). Diabetes was present in 46{\%} of pancreatic cancers and 55{\%} of resectable tumors. In pancreatic cancer with diabetes, the sensitivity of IAPP was only 50{\%}. In resectable cancer it was 27{\%}. Conclusions: IAPP is elevated in pancreatic cancer but is not sensitive enough to replace or complement existing tests. Diabetes occurs early and frequently in pancreatic cancer. Development of a sensitive and specific marker for pancreatic-associated diabetes might lead to diagnosis of resectable pancreatic cancer.",
author = "Chari, {Suresh T} and Klee, {George G.} and Miller, {Laurence J} and Massimo Raimondo and DiMagno, {Eugene P.}",
year = "2001",
language = "English (US)",
volume = "121",
pages = "640--645",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Islet amyloid polypeptide is not a satisfactory marker for detecting pancreatic cancer

AU - Chari, Suresh T

AU - Klee, George G.

AU - Miller, Laurence J

AU - Raimondo, Massimo

AU - DiMagno, Eugene P.

PY - 2001

Y1 - 2001

N2 - Background & Aims: Islet amyloid polypeptide (IAPP) levels are elevated in pancreatic cancer and may be a useful marker of pancreatic cancer-associated diabetes. The aim of this study was to compare the sensitivity and specificity for pancreatic cancer of IAPP with that of CA19-9, examine clinical characteristics of diabetes in pancreatic cancer, and define the relationship of lAPp to diabetes of pancreatic cancer. Methods: Fasting serum glucose, IAPP, and CA 19-9 were measured in 130 subjects with pancreatic cancer, 250 subjects with other pancreatic and peripancreatic diseases, and 116 controls. In pancreatic cancer patients, we noted tumor stage and the presence and duration of diabetes. Results: IAPP was markedly elevated in pancreatic cancer, especially in patients with diabetes. However, the sensitivity of IAPP for pancreatic cancer was less than that of CA 19-9 (40% vs. 75%; P < 0.001). Diabetes was present in 46% of pancreatic cancers and 55% of resectable tumors. In pancreatic cancer with diabetes, the sensitivity of IAPP was only 50%. In resectable cancer it was 27%. Conclusions: IAPP is elevated in pancreatic cancer but is not sensitive enough to replace or complement existing tests. Diabetes occurs early and frequently in pancreatic cancer. Development of a sensitive and specific marker for pancreatic-associated diabetes might lead to diagnosis of resectable pancreatic cancer.

AB - Background & Aims: Islet amyloid polypeptide (IAPP) levels are elevated in pancreatic cancer and may be a useful marker of pancreatic cancer-associated diabetes. The aim of this study was to compare the sensitivity and specificity for pancreatic cancer of IAPP with that of CA19-9, examine clinical characteristics of diabetes in pancreatic cancer, and define the relationship of lAPp to diabetes of pancreatic cancer. Methods: Fasting serum glucose, IAPP, and CA 19-9 were measured in 130 subjects with pancreatic cancer, 250 subjects with other pancreatic and peripancreatic diseases, and 116 controls. In pancreatic cancer patients, we noted tumor stage and the presence and duration of diabetes. Results: IAPP was markedly elevated in pancreatic cancer, especially in patients with diabetes. However, the sensitivity of IAPP for pancreatic cancer was less than that of CA 19-9 (40% vs. 75%; P < 0.001). Diabetes was present in 46% of pancreatic cancers and 55% of resectable tumors. In pancreatic cancer with diabetes, the sensitivity of IAPP was only 50%. In resectable cancer it was 27%. Conclusions: IAPP is elevated in pancreatic cancer but is not sensitive enough to replace or complement existing tests. Diabetes occurs early and frequently in pancreatic cancer. Development of a sensitive and specific marker for pancreatic-associated diabetes might lead to diagnosis of resectable pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=0034837496&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034837496&partnerID=8YFLogxK

M3 - Article

C2 - 11522748

AN - SCOPUS:0034837496

VL - 121

SP - 640

EP - 645

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 3

ER -